Notice of Allowance - patent protection US
Biomedical Bonding AB has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The unique formulation enables strong adhesion between substrates and the primer is an important part of BMB’s Bonevolent™ technology that allows surgeons to do on-site customizable bone fracture fixations.“This patent will broaden our IP protection in key geographical areas. It is an important strategic step for us when introducing our appreciated novel Bonevolent™ technology to the US market”, comments Evelina Mikaelson, CEO, Biomedical Bonding AB.